Bevacizumab Biosimilars Market Outlook Highlights The Next Major Growth Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Bevacizumab Biosimilars Market Revenue Growth Supported By A CAGR Of 2.42% Through 2030
The bevacizumab biosimilars market has experienced notable expansion in recent years, with projections showing an increase from $1.64 billion in 2025 to $1.77 billion in 2026, representing a compound annual growth rate (CAGR) of 7.5%. This historical growth has been driven by factors such as the expiration of patents on reference bevacizumab, a growing incidence of cancer, a higher demand for affordable biologic treatments, government support promoting biosimilar adoption, and progress in recombinant DNA technology.
The bevacizumab biosimilars market is projected to experience robust expansion over the coming years, reaching a valuation of $2.42 billion by 2030 with a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is driven by several key factors, including a rising number of biosimilar approvals, the expansion of markets in developing regions, the integration of artificial intelligence into drug development processes, a growing preference for outpatient oncology care, and increased strategic alliances among pharmaceutical companies. Key trends shaping this period include the broader uptake of biosimilars within oncology, the availability of cost-effective treatment options, an increase in regulatory clearances for biosimilars, the widening reach of hospital and retail pharmacy networks, and the emergence of more specialized cancer treatment centers.
Download A Free Sample Report For Comprehensive Market Insights:
Bevacizumab Biosimilars Market Development Factors: Which Trends Are Supporting Demand?
The anticipated expansion of the bevacizumab biosimilar market is being driven by the growing number of cancer cases. Cancer incidence describes the count of newly diagnosed cancer cases within a defined population over a specified timeframe. Bevacizumab, a biologic agent, works by blocking tumor angiogenesis, resulting in tumor reduction and halted growth, and it demonstrates comparable effectiveness and safety to original biologics when used for patients with advanced non-small cell lung cancer or metastatic colorectal cancer. As an example, data from NHS England, a UK governmental body, revealed in October 2025 that 354,820 new cancer diagnoses were recorded in England during 2023—an increase of 8,605 from the previous year. Consequently, the upward trend in cancer prevalence is fueling demand for bevacizumab biosimilars.
Bevacizumab Biosimilars Market Segment Outlook: Which Categories Are Expanding The Fastest?
The bevacizumab biosimilars market covered in this report is segmented –
1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer
Bevacizumab Biosimilars Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the bevacizumab biosimilars market are driving innovation with next-generation formulations designed for expanded indications, aimed at satisfying the growing need for more flexible and economical biologic treatments in both oncology and non-oncology fields. These enhanced formulations adapt the core bevacizumab antibody for alternative delivery methods or uses beyond cancer, such as ophthalmology, or for easier patient dosing schedules, all while preserving the VEGF-neutralizing mechanism seen in conventional intravenous bevacizumab. A notable example occurred in March 2024, when Dr. Reddy’s Laboratories, a pharmaceutical firm based in India, introduced Versavo (bevacizumab) in the UK as a high-quality biosimilar to Avastin, specifically developed for oncology purposes, thereby making treatments for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more accessible to a broader patient population. Supplied in 100 mg and 400 mg single-use vials, Versavo aligns with standard bevacizumab dosing regimens while offering a cost-effective biosimilar alternative that eases the financial strain on healthcare systems and patients relying on anti-VEGF therapy.
Bevacizumab Biosimilars Market Key Companies And Competitive Benchmarking
Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA
Access The Complete Bevacizumab Biosimilars Market Report:
Bevacizumab Biosimilars Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
